Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Circulation Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1253/circj.66.149PMID 11999639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure

  2005cited by this paper
• Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033.

  2000cited by this paper
• Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.

  2000cited by this paper
• Pimobendan inhibits the activation of transcription factor NF-κB

  2000cited by this paper
• Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild to moderate heart failure.

  2000cited by this paper
• A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.

  1999cited by this paper
• New insights into the pathophysiological role for cytokines in heart failure.

  1999cited by this paper
• Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis.

  1999cited by this paper
• Hemodynamic characteristics during treadmill and bicycle exercise in chronic heart failure: mechanism for different responses of peak oxygen uptake.

  1999cited by this paper
• The time from anaerobic threshold (AT) to respiratory compensation point reflects the rate of aerobic and anaerobic metabolism after the AT in chronic heart failure patients.

  1999cited by this paper
• A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure

  1998cited by this paper
• Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial.

  1998cited by this paper
• Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure

  1998cited by this paper
• Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo.

  1998cited by this paper
• Reversal of phosphate induced decreases in force by the benzimidazole pyridazinone, UD-CG 212 CL, in myofilaments from human ventricle

  1997cited by this paper
• Mechanoenergetic effect of pimobendan in failing dog hearts.

  1997cited by this paper
• New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.

  1997cited by this paper
• Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.

  1997cited by this paper
• Circulating interleukin-6 in severe heart failure.

  1997cited by this paper
• Sphingosine Mediates the Immediate Negative Inotropic Effects of Tumor Necrosis Factor-α in the Adult Mammalian Cardiac Myocyte*

  1997cited by this paper
• Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages.

  1996cited by this paper
• Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.

  1996cited by this paper
• Accurate measurement of left ventricular ejection fraction by three-dimensional echocardiography. A comparison with radionuclide angiography.

  1996cited by this paper
• Differential modulation of cytokine production by drugs: implications for therapy in heart failure.

  1996cited by this paper
• Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate.

  1995cited by this paper
• Will calcium sensitizers play a role in the treatment of heart failure?

  1995cited by this paper
• Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death.

  1995cited by this paper
• Increased circulating cytokines in patients with myocarditis and cardiomyopathy.

  1994cited by this paper
• Stability of human atrial natriuretic peptide in blood samples.

  1994cited by this paper
• Long-term efficacy and safety of Pimobendan in moderate heart failure: A double-blind parallel 6-month comparison with enalapril

  1994cited by this paper
• Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.

  1994cited by this paper
• Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.

  1993cited by this paper
• Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart.

  1993cited by this paper
• Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy.

  1993cited by this paper
• The epidemiology of heart failure: the Framingham Study.

  1993cited by this paper
• Inodilator therapy for heart failure. Early, late, or not at all?

  1993cited by this paper
• Effects of vesnarinone on morbidity and mortality in patients with heart failure

  1993cited by this paper
• The development of positive inotropic agents for chronic heart failure: how have we gone astray?

  1993influential reference
• Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.

  1992cited by this paper
• Evaluation of functional capacity of patient with congestive heart failure

  1992cited by this paper
• What do the newer inotropic drugs have to offer?

  1992cited by this paper
• Negative inotropic effects of cytokines on the heart mediated by nitric oxide.

  1992cited by this paper
• A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.

  1992cited by this paper
• Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

  1991cited by this paper
• Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

  1990cited by this paper
• Cardiovascular Effects and Plasma Level Profile of Pimobendan (UD‐CG 115 BS) and Its Metabolite UD‐CG 212 in Patients with Congestive Heart Failure After Single and Repeated Oral Dosing

  1989cited by this paper
• Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness.

  1989cited by this paper
• Calcium-sensitivity modulation of cardiac myofibrillar proteins.

  1989cited by this paper
• Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy.

  1989cited by this paper
• Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses.

  1988cited by this paper
• Sensitization of Dog and Guinea Pig Heart Myofilaments to Ca2+Activation and the Inotropic Effect of Pimobendan: Comparison With Milrinone

  1988cited by this paper
• Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent.

  1988cited by this paper
• [Interleukin 1 and tumor necrosis factor].

  1987cited by this paper
• Tables of the number of patients required in clinical trials using the logrank test.

  1982cited by this paper
• Assessment of Left Ventricular Ejection Fraction and Volumes by Real-time, Two-dimensional Echocardiography: A Comparison of Cineangiographic and Radionuclide Techniques

  1979cited by this paper
• Comparative value of eight M-mode echocardiographic formulas for determining left ventricular stroke volume. A correlative study with thermodilution and left ventricular single-plane cineangiography.

  1979cited by this paper

• Chronotropic, Inotropic, and Lusitropic Effects of Flavonoids.

  2026cites this paper
• JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.

  2025cites this paper
• JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.

  2025cites this paper
• Contemporary Use of Oral Inotropes in the Outpatient Treatment of Heart Failure: Analysis of a Japanese Nationwide Database

  2025cites this paper
• Reinforcement of pimobendan with guideline-directed medical therapy may reduce the rehospitalization rates in patients with heart failure: retrospective cohort study

  2024influential citation
• Multifaced risk factors and clinical impact of a deep Y descent in patients with heart failure irrespective of RV-PA coupling

  2024cites this paper
• Targeting Key Inflammatory Mechanisms Underlying Heart Failure: A Comprehensive Review

  2023cites this paper
• Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease

  2023cites this paper
• Regional Variation in the Clinical Practice and Prognosis in Patients With Heart Failure With Reduced Ejection Fraction in Japan　- A Report From the Japanese Registry of Acute Decompensated Heart Failure (JROADHF).

  2023cites this paper
• Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review.

  2023cites this paper
• Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs

  2023cites this paper
• Inotropic therapies in heart failure and cardiogenic shock: an educational review.

  2021cites this paper
• Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results

  2021cites this paper
• Pharmacological Treatment of Chronic Heart Failure

  2020cites this paper
• Home Therapies in Advanced Heart Failure: Inotropes and Diuretics

  2020cites this paper
• Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)

  2020cites this paper
• Long-term management of congestive heart failure secondary to mitral stenosis in a ring-tailed lemur (Lemur catta).

  2020cites this paper
• NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases

  2019cites this paper
• Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis

  2019cites this paper
• Cardiovascular Pharmacotherapeutics

  2019cites this paper
• Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction

  2019cites this paper
• Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies

  2019cites this paper
• Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs

  2018cites this paper
• Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy

  2017cites this paper
• The Role of Positive Inotropic Drugs in the Treatment of Older Adults with Heart Failure and Reduced Ejection Fraction.

  2017cites this paper
• Efficacy of Mokuboito in Patients with Severe Intractable Heart Failure

  2016cites this paper
• Prognostic Impact of Functional Mitral Regurgitation in Patients Admitted With Acute Decompensated Heart Failure.

  2016cites this paper
• Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.

  2016cites this paper
• Heart failure epidemiology and novel treatments in Japan: facts and numbers

  2016cites this paper
• Low-dose oral pimobendan emancipates patients with severe ischemic pump failure from intravenous catecholamine infusion for cardiogenic shock.

  2016cites this paper
• Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.

  2015cites this paper
• Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension

  2015cites this paper
• Stage‐dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure

  2015cites this paper
• Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure

  2014cites this paper
• Proceedings of the pre-BSAVA Satellite Meeting of the Veterinary Cardiovascular Society

  2013cites this paper
• Depressed Frank-Starling mechanism in the left ventricular muscle of the knock-in mouse model of dilated cardiomyopathy with troponin T deletion mutation ΔK210.

  2013cites this paper
• What are the most useful predictors of cardiac mortality in patients post myocardial infarction?

  2013cites this paper
• Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure.

  2013cites this paper
• Cardiac Involvement of Hepatitis B and C Virus Infection

  2013cites this paper
• Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.

  2012cites this paper
• Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011).

  2012cites this paper
• The effect of pimobendan on left atrial pressure in dogs with mitral valve regurgitation.

  2011cites this paper
• for Chapter 13 Inotropic Agents

  2011cites this paper
• Use of pimobendan in 170 cats (2006-2010).

  2011cites this paper
• Pharmaceutical and nutraceutical effects of Pinus pinaster bark extract

  2011cites this paper
• Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.

  2011cites this paper
• Inotropic Therapy for End-Stage Heart Failure Patients

  2010cites this paper
• Carvedilol can prevent cardiac events in Duchenne muscular dystrophy.

  2010cites this paper
• Assessment of myocardial blood perfusion improved by CD151 in a pig myocardial infarction model

  2009cites this paper
• A health-related quality of life questionnaire in symptomatic patients with heart failure: validity and reliability of a Japanese version of the MRF28.

  2009cites this paper
• Prevalence and prognosis of patients with heart failure in Tokyo: a prospective cohort of Shinken Database 2004-5.

  2009cites this paper
• Heart Disease in Asia Shigetake Sasayama

  2008cites this paper
• Intervention for apoptosis in cardiomyopathy

  2008cites this paper
• Heart disease in Asia.

  2008cites this paper
• Clinical efficacy and cost-benefit analysis of nocturnal home oxygen therapy in patients with central sleep apnea caused by chronic heart failure.

  2007cites this paper
• French maritime pine bark extract inhibits viral replication and prevents development of viral myocarditis.

  2007cites this paper
• Rationale and design of a randomized trial to assess the effects of diuretics in heart failure: Japanese Multicenter Evaluation of Long- vs Short-Acting Diuretics in Congestive Heart Failure (J-MELODIC).

  2007cites this paper
• Effects of pimobendan for mitral valve regurgitation in dogs.

  2007cites this paper
• Should cardiologists treat Cheyne-Stokes respiration and congestive heart failure with oxygen, bi-level/continuous positive airway pressures or drugs alone?

  2006cites this paper
• STATE OF THE ART LECTURES THERAPY OF CONGESTIVE HEART FAILURE IN DOGS WITH INODILATORS

  2006cites this paper
• Levosimendan in patients with ischaemic heart disease

  2006cites this paper
• Acute heart failure: inotropic agents and their clinical uses

  2006cites this paper
• Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.

  2006cites this paper
• Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy.

  2006cites this paper
• Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration.

  2006cites this paper
• Prognostic impact of ventilatory efficiency in heart disease patients with preserved exercise tolerance.

  2006cites this paper
• New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension

  2006cites this paper
• Assessment of quality of life with 5 different scales in patients participating in comprehensive cardiac rehabilitation after acute myocardial infarction.

  2005cites this paper
• [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].

  2005cites this paper
• Wenn die Myofilamente sensibel werden

  2005cites this paper
• Calcium Sensitizers, a New Class of Inodilators

  2005cites this paper
• An emerging role for calcium sensitisation in the treatment of heart failure

  2005cites this paper
• Phosphodiesterase III inhibitors for heart failure.

  2005cites this paper
• Use of pimobendan in the management of heart failure.

  2004cites this paper
• Anti-inflammatory therapy for heart failure.

  2004cites this paper
• Optimising Outcomes in End-Stage Heart Failure

  2004cites this paper
• Potential candidates for cardiac resynchronization therapy in Japanese patients with idiopathic dilated cardiomyopathy--a Niigata multicenter study of DCM--.

  2004cites this paper
• The therapeutic potential of novel cardiotonic agents

  2003cites this paper
• The role of Ca++-sensitizers for the treatment of heart failure

  2003cites this paper
• β-Blocker Therapy Combined with Low-Dose Pimobendan in Patients with Idiopathic Dilated Cardiomyopathy and Chronic Obstructive Pulmonary Disease: Report on Two Cases

  2002cites this paper
• Inotropic Agents and Immune Modulation

  2002influential citation
• Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.

  2002cites this paper
• Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases.

  2002cites this paper
• Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy.

  2002cites this paper